- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ISR IMMUNE SYSTEM REGULATION Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTELLIA THERAPEUTICS | 10,100 | -3,81 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million | CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,115 | +0,90 % | PacBio Appoints Mark Van Oene as President and Chief Executive Officer | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of high-quality, highly accurate sequencing solutions,... ► Artikel lesen | |
| ATAIBECKLEY | 6,250 | -0,79 % | Emyria vor Meilenstein: Erste Sydney-Klinik ist startbereit für Psychdelika-Patienten | ||
| BIOMERIEUX | 71,10 | 0,00 % | bioMérieux Highlights Positive Impacts of Rapid, Accurate Diagnostics for Patients and Accepts Industry Awards at ADLM 2026 | SALT LAKE CITY, Aug. 7, 2026 /PRNewswire/ -- bioMérieux, a world leader in the field of in vitro diagnostics, leveraged this year's 2026 Association for Diagnostics & Laboratory Medicine... ► Artikel lesen | |
| BIO GREEN MED SOLUTION | 0,869 | 0,00 % | Morning Market Movers: Bio Green Med Solution, Solidion Technology, Indaptus Therapeutics, Merlin, Inc. See Big Swings | BEIJING (dpa-AFX) - At 7:20 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ANAPTYSBIO | 47,400 | -0,98 % | Alphyn Capital on Its Special-Situation Investment: AnaptysBio (ANAB) | ||
| GENUS | 26,000 | 0,00 % | Genus Launches £60 Mln Share Buyback Programme | ||
| AKESO | 10,090 | 0,00 % | CICC Cuts AKESO TP to HKD120, Focuses on Harmoni-2 and Harmoni-3 Data | ||
| MEIRAGTX | 11,600 | +1,75 % | MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec) | MeiraGTx to receive up to $375 million in non-dilutive cash and up to $25 million in equity investmentFollowing regulatory approval, Oberland Capital to receive low single-digit capped royalties on... ► Artikel lesen | |
| ABIONYX PHARMA | 1,856 | 0,00 % | ABIONYX Pharma Reaches Another Key Milestone in the Industrialization of CER-001 by Entering into a Strategic Partnership with TEXCELL (ABL Diagnostics) for the Viral Safety and Clearance of Biologics | Preparation of validation batches for the CER-001 bioproduction process based on viral safety studies A key step in the industrial and regulatory dossier toward a future market launch for... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 1,970 | 0,00 % | XTL Biopharmaceuticals Ltd.: XTL Completed the Acquisition of Psyga Bio Ltd. | expands its IP portfolio to clinical-stage biopharmaceutical assets XTL Biopharmaceuticals (XTL) Completes the Acquisition of Psyga Bio and Establishes Psychedelic Biotechnology Platform At a historic... ► Artikel lesen | |
| MAAT PHARMA | 2,710 | 0,00 % | MaaT Pharma Presents the Results of its Annual General Meeting and Provides a Statement on its Half-Year Liquidity Contract | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| ISOFOL MEDICAL | 0,051 | +0,20 % | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January - June 2026 | GOTHENBURG, Sweden, August 25, 2026 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), ("Isofol" or the "Company"), announced today that the company's interim report for January - June 2026 is... ► Artikel lesen | |
| ERASCA | 16,030 | 0,00 % | FDA Fast Track Puts Erasca's (ERAS) Pancreatic Bet Center Stage | ||
| QIAGEN | 36,615 | -0,01 % | QIAGEN N.V. - 6-K, Report of foreign issuer |
Das Unternehmen ISR IMMUNE SYSTEM REGULATION HOLDING AB kann der Branche Biotechnologie zugeordnet werden.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ISR IMMUNE SYSTEM REGULATION HOLDING AB finden Sie auf Wallstreet Online.